Results 171 to 180 of about 1,197,543 (390)

INFANTILE PSEUDOLEUKEMIC ANEMIA. [PDF]

, 1906
JosephW. Hunt
openalex   +1 more source

Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B‐cell malignancies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of this study was to assess differences between Chinese and White patients in pharmacokinetics (PK) of, and clinical response to, acalabrutinib and its pharmacologically active major metabolite, ACP‐5862, to support recommended dosing in Chinese patients with B‐cell malignancies.
Tingting Yao, Junjie Ding, Shringi Sharma, Yunfei Li, Qianwei Xu, Peiming Ma   +5 more
wiley   +1 more source

THE NATURE AND VARIETIES OF ANEMIA. [PDF]

, 1897
ALFRED STENGEL
openalex   +1 more source

The QUEST initiative anemia study in ESRD: rationale and study protocol [PDF]

, 2007
No ...
Del Vecchio, Lucia, Deska-Slizien, Alicja, Jager, Kitty J., Locatelli, Francesco, Martins Prata, Mateus, Mauri, Joan M., Metsarinne, Kaj, Mircescu, Gabriel, Siamopoulos, Kostas C., Stel, Vianda S., Van Biesen, Wim, Wauters, Jean Pierre, Will, Eric, Zoccali, Carmine   +13 more
core  

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Dipeptidyl peptidase‐1 (DPP‐1) inhibitors have been studied for the treatment of neutrophil‐mediated inflammatory diseases including bronchiectasis, bronchial asthma and cystic fibrosis. This study evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of DPP‐1 inhibitor HSK31858 in healthy Chinese volunteers.
Yuhao Wang, Chao Yu, Mengyue Hu, Lu Wang, Meixia Chen, Hanmo Liu, Nan Wu, Jie Hou   +7 more
wiley   +1 more source

BLOOD DEPLETION TO 296,000 IN PERNICIOUS ANEMIA WITH RECOVERY. [PDF]

, 1908
WILLARD J. STONE
openalex   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano   +4 more
wiley   +1 more source

PENYAKIT-PENYAKIT YANG MENYERTAI KEJADIAN KEJANG DEMAM ANAK DI RSUP Dr. KARIADI SEMARANG [PDF]

, 2014
Latar Belakang : Kejang demam dapat dikatagorikan menjadi kejang demam simplek dan kejang demam komplek. Penyakit-penyakit yang menyertai pada kejang demam harus diwaspadai bagi para klinisi karena agar dapat mencegah kerusakan otak yang lebih buruk ...
Nugroho, Wisnu Wahyu, Putranti, Alifiani Hikmah   +1 more
core   +1 more source

Safety of sulfamethoxazole–trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta‐analysis with active comparator disproportionality analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Sulfamethoxazole–trimethoprim (SMX‐TMP) is a widely used antibiotic for treating bacterial infections, but its safety in adult outpatients remains understudied. This systematic review and meta‐analysis evaluated the safety profile of SMX‐TMP and identified critical research gaps.
Rebecca Preyra, Lujain Ez Eddin, Fatemeh Ahmadi, Atefeh Jafari, Flory T. Muanda   +4 more
wiley   +1 more source

Production of Microcytic Hypochromic Anemia in Puppies on Synthetic Diet Deficient in Rat Antidermatitis Factor (Vitamin B6) [PDF]

, 1938
Paul J. Fouts, O. M. Helmer, Samuel Lepkovsky, Thomas H. Jukes   +3 more
openalex   +1 more source